Novartis’ breast cancer trial of Kisqali reveals 28.5% risk reduction

[cafead]

via Novartis has reported a 28.5% reduced risk of breast cancer recurrence in an updated analysis from the Phase III NATALEE trial of Kisqali (ribociclib), when combined with endocrine therapy.

article source